Physician profile
Frances Beard
NPI 1770550659
$9,323.53
in general payments reported to CMS, 2019-2025
30 companies · $1,668 in 2025
The $1,668 reported for 2025 was more than what 82% of Dermatopathology (Dermatology) providers received nationally (typical 2025 total: $251).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,194 · 2020: $265 · 2021: $807 · 2022: $1,773 · 2023: $1,606 · 2024: $2,010 · 2025: $1,668.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,094 · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,093.83 |
| Education | $189.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,430.99 | 2019-2025 | Skyrizi, Rinvoq |
| Genzyme Corporation | $1,083.39 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,076.40 | 2019-2025 | |
| Janssen Biotech, INC. | $763.78 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Sun Pharmaceutical Industries INC. | $615.38 | 2021-2025 | Ilumya, Odomzo, Blu-U |
| Regeneron Healthcare Solutions, INC. | $457.12 | 2019-2025 | Dupixent |
| Lilly USA, LLC | $411.62 | 2019-2025 | Taltz, Ebglyss |
| Genentech USA, INC. | $350.50 | 2019-2022 | |
| Leo Pharma INC. | $311.04 | 2019-2025 | Adbry, Anzupgo |
| Ucb, INC. | $274.13 | 2019-2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $273.25 | 2022-2025 | Sotyktu |
| Incyte Corporation | $222.39 | 2022-2025 | Opzelura |
| Galderma Laboratories, L.P. | $206.99 | 2019-2025 | Nemluvio |
| Pfizer INC. | $193.02 | 2019-2025 | |
| Kerecis Limited | $97.17 | 2022-2024 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $75.63 | 2023-2024 | Vtama |
| Hydrofera LLC | $61.57 | 2024 | Hydrofera Blue, Hydrofera Blue Ready - Border |
| Organogenesis INC. | $58.76 | 2024-2025 | Novachor, Cygnus Dual |
| Arcutis Biotherapeutics, INC. | $57.23 | 2024-2025 | Zoryve |
| Misonix INC | $50.71 | 2019 | |
| Amgen INC. | $43.30 | 2023 | Otezla |
| Revance Therapeutics, INC. | $41.35 | 2025 | Daxxify |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $35.72 | 2020-2024 | Jublia |
| Biofrontera INC. | $29.71 | 2021-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Sweetbio, INC. | $21.24 | 2023 | Veris |
| Mckesson Medical-Surgical, INC. | $20.00 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.85 | 2022 | |
| Medimetriks Pharmaceuticals, INC. | $17.60 | 2021 | |
| Organon LLC | $16.66 | 2025 | |
| Mayne Pharma Commercial LLC | $8.03 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frances Beard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.